Clinical Trials Browser

Lung Neoplasms × tislelizumab × Clear all

NCT04699188 2026-03-18

KontRASt-01

Phase 1/2 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT07120282 2026-03-09

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06877299 2026-01-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04047186 2025-09-23

Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules

Phase 2 Completed

Lung Neoplasms, Multiple Pulmonary Nodules

NCT05014815 2025-09-16

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

272 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT06598527 2025-05-29

SACTION2401

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06332274 2025-05-13

UMBRELLA

Phase 3 Recruiting

GastrointestinalSarcomaThoracic

Colonic Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT06883552 2025-03-19

An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06749860 2024-12-27

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

Phase 2 Recruiting

Lung Neoplasms

NCT06749886 2024-12-27

An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting

Phase 2 Recruiting

Lung Neoplasms

NCT03432598 2024-10-23

Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer

Phase 2 Completed

Lung Neoplasms